A novel four‐gene signature predicts immunotherapy response of patients with different cancers

BACKGROUND: Immune checkpoint blockade (ICB) therapy has demonstrated favorable clinical efficacy, particularly for advanced or difficult‐to‐treat cancer types. However, this therapy is ineffective for many patients displaying lack of immune response or resistance to ICB. This study aimed to establi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuanli, Ni, Mingyue, Li, Lamei, Wang, Junyan, Tu, Zhenzhen, Zhou, Haisheng, Zhang, Siping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279975/
https://www.ncbi.nlm.nih.gov/pubmed/35588138
http://dx.doi.org/10.1002/jcla.24494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279975/
https://www.ncbi.nlm.nih.gov/pubmed/35588138
http://dx.doi.org/10.1002/jcla.24494

Ejemplares similares